Should I buy or sell Greenwich LifeSciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLSI shares. View GLSI analyst ratings or view top-rated stocks .

What is Greenwich LifeSciences' stock price target for 2024?

1 Wall Street analysts have issued 1-year price objectives for Greenwich LifeSciences' shares. Their GLSI share price targets range from $36.00 to $36.00. On average, they anticipate the company's share price to reach $36.00 in the next year. This suggests a possible upside of 186.6% from the stock's current price. View analysts price targets for GLSI or view top-rated stocks among Wall Street analysts .

How have GLSI shares performed in 2024?

Greenwich LifeSciences' stock was trading at $10.52 at the start of the year. Since then, GLSI shares have increased by 19.4% and is now trading at $12.56. View the best growth stocks for 2024 here .

When is Greenwich LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our GLSI earnings forecast .

When did Greenwich LifeSciences IPO?

Greenwich LifeSciences (GLSI) raised $7 million in an IPO on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital served as the underwriter for the IPO.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free GLSI Stock Alerts

$12.77

-0.12 (-0.93%)

(As of 03:02 PM ET)

Compare

Today's Range: $12.51
▼
$13.18
50-Day Range: $8.31
▼
$20.32
52-Week Range: $7.58
▼
$21.44

Volume: 12,821 shs
Average Volume: 45,467 shs
Market Capitalization: $164.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.00

Get Greenwich LifeSciences alerts:

Greenwich LifeSciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 186.6% Upside
$36.00 Price Target
Short Interest: Healthy
2.41% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.31
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$327,722 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars

Medical Sector

520th out of 918 stocks

Pharmaceutical Preparations Industry

236th out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
Greenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Greenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.41% of the float of Greenwich LifeSciences has been sold short.
Short Interest Ratio / Days to Cover
Greenwich LifeSciences has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Greenwich LifeSciences has recently increased by 2.48%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Greenwich LifeSciences does not currently pay a dividend.
Dividend Growth
Greenwich LifeSciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLSI.

1.8

News and Social Media Coverage

News Sentiment
Greenwich LifeSciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Greenwich LifeSciences this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $327,722.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
52.86% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 4.16% of the stock of Greenwich LifeSciences is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Greenwich LifeSciences is -17.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Greenwich LifeSciences is -17.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Greenwich LifeSciences has a P/B Ratio of 12.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Greenwich LifeSciences Stock (NASDAQ:GLSI)

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

GLSI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLSI Stock News Headlines

April 4, 2024 | insidertrades.com

Snehal Patel Buys 3,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

March 27, 2024 | insidertrades.com

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,500 Shares

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 23, 2024 | insidertrades.com

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,500 Shares

April 17, 2024 | americanbankingnews.com

Greenwich LifeSciences (NASDAQ:GLSI) versus Zai Lab (NASDAQ:ZLAB) Head-To-Head Analysis

April 15, 2024 | markets.businessinsider.com

GLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023

March 13, 2024 | globenewswire.com

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

March 12, 2024 | globenewswire.com

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 7, 2024 | finance.yahoo.com

Greenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional Shares

February 28, 2024 | markets.businessinsider.com

Expanding Horizons: Bullish Buy Rating as Greenwich LifeSciences’s Breast Cancer Trial Goes Pan-European

February 27, 2024 | msn.com

Greenwich LifeSciences stock jumps 8% on Phase 3 study expansion

February 27, 2024 | finanznachrichten.de

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

February 27, 2024 | globenewswire.com

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

February 23, 2024 | benzinga.com

Greenwich LifeSciences Stock (NASDAQ:GLSI) Dividends: History, Yield and Dates

February 22, 2024 | finanznachrichten.de

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

February 22, 2024 | msn.com

Greenwich Lifesciences announces acceptance for Flamingo-01 trial by EMA

February 22, 2024 | finance.yahoo.com

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

February 22, 2024 | globenewswire.com

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

February 21, 2024 | realmoney.thestreet.com

2 Rare Insider Buys in a Frothy Market

February 20, 2024 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Greenwich LifeSciences: Here's What You Need To Know

February 14, 2024 | msn.com

Why Greenwich Lifesciences (GLSI) Stock Is Skyrocketing

February 14, 2024 | morningstar.com

Greenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer Immunotherapy

February 14, 2024 | globenewswire.com

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

December 21, 2023 | bbc.co.uk

Greenwich: Closed pub reopens as community hub

December 11, 2023 | finance.yahoo.com

Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently

December 2, 2023 | yahoo.com

Greenwich, United States - Weather Forecasts | Maps | News - Yahoo Weather

See More Headlines

Receive GLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GLSI
CUSIP: N/A
CIK: 1799788
Web: www.greenwichlifesciences.com
Phone: 832-819-3232
Fax: N/A
Employees: 3
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.00
High Stock Price Target: $36.00
Low Stock Price Target: $36.00
Potential Upside/Downside: +180.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -80.50%
Return on Assets: -78.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 30.79
Quick Ratio: 30.79

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.03 per share
Price / Book: 12.46

Miscellaneous

Outstanding Shares: 12,880,000
Free Float: 6,071,000
Market Cap: $165.25 million
Optionable: Not Optionable
Beta: 1.38

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Snehal S. Patel (Age 61)
CEO, CFO & Director
Comp: $1.01M
Mr. Eric Rothe (Age 49)
Founder & Independent Director
Dr. Frank Joseph Daugherty M.D. (Age 74)
Chief Medical Officer & Director
Dr. Jaye L. Thompson Ph.D. (Age 58)
Vice President Clinical & Regulatory Affairs
Dr. Christine T. Fischette Ph.D. (Age 73)
VP of Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLSI Stock Analysis - Frequently Asked Questions

Should I buy or sell Greenwich LifeSciences stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLSI shares.
View GLSI analyst ratings or view top-rated stocks.
What is Greenwich LifeSciences' stock price target for 2024?: 1 Wall Street analysts have issued 1-year price objectives for Greenwich LifeSciences' shares. Their GLSI share price targets range from $36.00 to $36.00. On average, they anticipate the company's share price to reach $36.00 in the next year. This suggests a possible upside of 186.6% from the stock's current price.
View analysts price targets for GLSI or view top-rated stocks among Wall Street analysts.
How have GLSI shares performed in 2024?: Greenwich LifeSciences' stock was trading at $10.52 at the start of the year. Since then, GLSI shares have increased by 19.4% and is now trading at $12.56.
View the best growth stocks for 2024 here.
When is Greenwich LifeSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our GLSI earnings forecast.

When did Greenwich LifeSciences IPO?: Greenwich LifeSciences (GLSI) raised $7 million in an IPO on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital served as the underwriter for the IPO.
How do I buy shares of Greenwich LifeSciences?: Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLSI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

Greenwich LifeSciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Greenwich LifeSciences Stock (NASDAQ:GLSI)

GLSI Stock Price History

GLSI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GLSI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™